|
Canada-0-CARTAGE Κατάλογοι Εταιρεία
|
Εταιρικά Νέα :
- USPNF810G_GC 1132_2017-01 - US Pharmacopeia (USP)
Residual HCPs have the potential to affect product quality, safety, and efficacy; therefore, the quantity of HCPs should be low The product purification processes must be optimized to consistently remove as many HCPs as feasible, with the goal of making the product as pure as possible
- Guidance for Industry: Considerations for Plasmid DNA Vaccines for . . .
As product development progresses, the level of host cell material should be further reduced, as technically and logistically feasible
- Frontiers | Residual host cell proteins: sources, properties, detection . . .
Host cell proteins (HCPs) are process-related impurities derived from host organisms used for recombinant protein production in biopharmaceutical manufacturing The generation of HCPs may lead to potential safety risks, such as immunogenicity, reduced drug efficacy and long-term side effects
- The future of host cell protein (HCP) identification during process . . .
Development and qualification of a high sensitivity, high throughput Q‐PCR assay for quantitation of residual host cell DNA in purification process intermediate and drug substance samples
- USP 1132. 1 : How to perform HCP analysis by MS - Alphalyse
It provides best practices for measuring residual host cell proteins (HCPs) in biologics using liquid chromatography–mass spectrometry (LC-MS MS) The chapter supports regulatory compliance by offering detailed guidance on method validation, system suitability, and quantitation of individual HCPs
- USP lt;1132 gt; Residual Host Cell Protein Measurement in Biopharmaceuticals
USP General Chapter <1132> provides a comprehensive, informational framework for controlling residual host cell proteins (HCPs)—process-related impurities from the production cell line (e g , CHO, E coli)
- Proteins Peptides Residual Host Cell Protein (HCP) Analysis
Residual host cell protein (HCP) is a major class of process-related impurities that regulatory agencies require manufacturers to demonstrate have been eliminated during the development of protein peptide biologics to ensure drug purity, manufacturing process consistency, and patient safety
- Validation Guidance for Residual Host Cell DNA Testing
Residual host-cell DNA impurities, measured in the final dosage form, must follow regulatory guidelines established by agencies such as the US FDA, European Medicines Agency (EMA), the World Health Organization (WHO), and other regional regulatory jurisdictions
- Direct Analysis of Residual Host Cell DNA by Droplet Digital PCR (ddPC
To develop and validate a droplet digital PCR (ddPCR) method (a newer generation PCR than conventional qPCR technology) for residual E coli host cell DNA quantification in protein
- Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-On . . .
The Food and Drug Administration (FDA or Agency) is establishing a public docket to collect information and comments on evaluating and mitigating the immunogenicity risk of host cell proteins (HCPs)
|
|